Resverlogix Corp. (TSX: RVX)
Health Care · Biotechnology · CA
CA$0.10
-5.00% today · +5.3% 1Y
Resverlogix Corp. (TSX: RVX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $25.00M and employs 17 people.
Over the last twelve months the share price has gained 5.3%, trading between 0.09 and 0.15.
Tweenvest scores Resverlogix Corp. across four factors: quality 5/100. Its strongest factor is quality.
RVX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.00M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 1.06
- 52-week high
- CA$0.15
- 52-week low
- CA$0.09
- Avg volume (3M)
- —
- Shares outstanding
- 344.29M
- Employees
- 17
- Next earnings
- —
About Resverlogix Corp.
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
- ISIN
- CA76128M1086
- Listed since
- May 7, 2004
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €875.40 | +1.30% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.